Tanzania

Pfizer Global Health Fellows

The Pfizer Global Health Fellows program utilizes the professional expertise of Pfizer employees through specialized volunteer assignments with nonprofit organizations to improve health care services for underserved communities around the world. Since 2003, more than 230 employees with a range of technical skills have served in 39 nations for 3-6 month assignments investing nearly 200,000 hours of skills-based service to help increase the capacity of nonprofits organizations providing health care to the underserved (in the reporting period, 54 Global Health Fellows were deployed).

Pfizer Diflucan Partnership

Pfizer created the Diflucan Partnership in 2000 to provide treatment for two AIDS-related fungal infections in developing countries. Since the program's inception, Pfizer has over provided USD 1.1 billion of products and its program partners distribute millions of Diflucan (fluconazole) treatments free of charge to governments and NGOs in 63 developing countries in Africa, Asia, the Caribbean and Latin America. Pfizer has also provided training and education materials to 20,000 healthcare professionals.

Pfizer - Azithromycin/chloroquine for Malaria

Pfizer, in partnership with Medicines for Malaria Venture (MMV) and London School of Hygiene and Tropical Medicine, is developing a fixed dose combination of azithromycin and chloroquine (AZCQ) for intermittent treatment of malaria in pregnant women (IPTp) in sub-Saharan Africa. IPTp is aimed at lowering the incidence of adverse pregnancy outcomes associated with malaria in pregnancy. Sulfadoxine/pyrimethamine (SP) is the current standard of care for IPTp in high transmission areas in Africa.

PATH Malaria Vaccine Initiative (MVI)

MVI works to link government, industry, and academia partners with field trial sites in malaria endemic countries as early as feasible in the development process.

Nurse Training in East Africa

Johnson & Johnson supports the Advanced Nursing Studies (ANS) and the Enrolled Nurses to Registered Nurses (ER-RN) programs at the Aga Khan University Health Sciences campus in Nairobi, Kenya. The program provides quality education and greater standards of evidence-based care to nurses and midwives from Kenya, Tanzania, and Uganda, to further develop their professional skills. The training, which includes some distance-learning approaches, prepares nurses to become registered nurses. More than 500 nursing students have benefited from this program.

Novo Nordisk: World Partner Project

The diabetes pandemic will undoubtedly affect developing countries' ability to grow and develop. The World Partner Project (WPP) was launched in 2001 to establish a foundation on which developing countries can build their own diabetes healthcare strategies and ultimately improve access to proper care. The WPP works with local partners, usually health ministries and/or patient organizations, and is funded by a grant from Novo Nordisk.

Novo Nordisk: Differential Pricing on Insulin

Among the targets for UN Millennium Development Goal 8 is a call for partnerships with pharmaceutical companies to provide access to affordable essential drugs in developing countries. Since 2001, Novo Nordisk has offered human insulin to the public health systems in Least Developed Countries (LDCs) at prices which do not to exceed 20% of the average price in Europe, Japan and North America. In 2009, Novo Nordisk offered this pricing scheme to all 49 LDCs, of which 36 used it to buy insulin at or below this price, compared to 32 in 2008.

Novartis TB DOTS Donation

Novartis is donating anti-TB medication to treat 500,000 patients in poor countries.

Novartis R&D for Malaria

Novartis is focusing on the development of a one-dose cure for P. falciparum, the most dangerous form of malaria, and a curative modality for P. vivax, the most frequent-occurring and widely distributed type of malaria.

Novartis Coartem

Coartem is the first World Health Organization-prequalified fixed-dose, artemisinin-based combination therapy (ACT) antimalarial, approved by stringent regulatory authorities and on the WHO Model List of Essential Medicines. Coartem is fast-acting and cures over 97% of patients after a 3-day treatment course. Coartem combines artemether, a derivative of artemisinin (from the Chinese medicinal plant Artemisia annua), with a synthetic substance, lumefantrine, which has not been used as a monotherapy.

Pages